No abstract available
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use*
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Bevacizumab
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / mortality
-
Breast Neoplasms / pathology*
-
Disease-Free Survival
-
Drug Approval
-
Female
-
Humans
-
Neoplasm Metastasis
-
Randomized Controlled Trials as Topic
-
Survival Rate
-
United States
-
United States Food and Drug Administration
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab